Effect Of Anemia In Patients On Peritoneal Dialysis Combined With Renal Anemia And Its Effect On Iron Metabolism And CRP

Objective: To investigate the effect of roxostat and erythropoietin in the department of the Fifth Affiliated Hospital of Xinjiang Uygur Autonomous Region.Method: in June2021 to August 2022,the fifth affiliated hospital of Xinjiang medical university and Xinjiang uygur autonomous region people’s hospital peritoneal dialysis after 1 year rule peritoneal dialysis with anemia patients with a total of 100 cases,according to the random number table generated random patients,divided into 55 cases,promoting erythropoietin treatment group 45 cases.General clinical data were collected,such as gender,age,dialysis age,24-hour urine output;laboratory data were collected,measuring blood lipid,white blood cell count,C-reactive protein number,red blood cell hematocrit,hemoglobin,platelet,ALT,ALT,ALT,serum albumin,blood creatinine,blood urea nitrogen,uric acid,calcium,phosphorus,magnesium,potassium,sodium and chloride;total iron binding force,serum iron,transferrin saturation,and ALPA.According to the generation of the random number table,the patients were randomly divided into the experimental group(roxostat group)and the control group(erythropoietin group).The differences between the relevant indicators of the experimental group and the control group were analyzed,and the related risk factors were analyzed,so as to provide new diagnosis and treatment ideas for the treatment of patients with peritoneal dialysis combined with renal anemia.Results: General data of patients: A total of 100 patients with anemia were included in this study,including 45 patients in EPO group,25 men,20 women,mean age(50.67 ± 10.81),55 patients,38 males,17 females,mean age(53.67 ±10.60),mean hemoglobin in EPO group was(105.71 ± 19.02)g/L,and(103.52 ±20.65)g/L hemoglobin.Comparison of general data and laboratory indicators in experimental group(roxostat)and control group(EPO): ALB,PLT,BUN,CREA,and parathyroid hormone indicators levels in EPO group were higher than roxostat group,with statistical significance(P<0.05).No significant differences were found in gender,dialysis age,24-hour urine volume,blood lipids,WBC,HGB,CRP,ALT,AST,UA,calcium,corrected calcium,phosphorus,magnesium,potassium,sodium,chlorine,total iron binding,serum iron,ferritin,and transferrin saturation.Conclusion: In the treatment of anemia,the improvement of the two drugs was similar,but in PD patients with CKD anemia,it could improve residual renal function,improve nutritional status and prevent secondary hyperparathyroidism.Therefore,we can speculate that roxostat is superior to EPO in the future treatment of PD patients with anemia.